Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of “Buy” from Analysts

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has earned a consensus recommendation of “Buy” from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year […]

Leave a Reply

Your email address will not be published.

Previous post Financial Comparison: Waldencast (NASDAQ:WALDW) vs. Duos Technologies Group (NASDAQ:DUOT)
Next post ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Rating of “Moderate Buy” by Analysts